Eli Lilly and Co. has made executive leadership changes and created neuroscience and immunology business units. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology.
 
Anne White, currently senior vice president and president of Lilly Oncology, will lead Lilly Neuroscience as senior vice president and president. Anne is an experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, Anne will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.
 
Jacob Van Naarden, currently chief executive officer of Loxo Oncology at Lilly, has been promoted to senior vice president, CEO of Loxo Oncology at Lilly and president, Lilly Oncology, and will be unifying these organizations. He also will join Lilly’s executive committee. Van Naarden has played an essential role in forging the Loxo Oncology at Lilly research and development program and in the success of its oncology pipeline. 
 
Patrik Jonsson will lead Lilly’s launched products and Phase 3 portfolio of medicines in dermatology, gastroenterology and rheumatology as president, Lilly Immunology, in addition to his ongoing responsibilities as senior vice president and president, Lilly USA and chief customer officer.  Lilly recently announced positive Phase 3 results for new biologic entities of mirikizumab for ulcerative colitis and lebrikizumab for atopic dermatitis.
 
Alfonso Zulueta, senior vice president and president of Lilly International, will retire at the end of 2021 after more than three decades with the company. Ilya Yuffa, currently senior vice president and president of Lilly Bio-Medicines, will succeed Zulueta to lead the company’s commercial operations in all markets outside the U.S., except for Canada. Yuffa previously served as vice president of U.S. Diabetes for Lilly USA and president and general manager of Lilly’s Italy Hub.
 
Mike Mason will continue to serve as senior vice president and president, Lilly Diabetes, with responsibility for the company’s launched products and Phase 3 portfolio of diabetes therapies, including the potential launch of tirzepatide for the treatment of type 2 diabetes.